OmniAb (OABI) vs Silence Therapeutics Plc American Depository Share (SLN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
OmniAb (OABI) has outperformed Silence Therapeutics Plc American Depository Share (SLN) over the past year, gaining 166.3% versus a gain of 81.3%. Over five years, OABI leads with a -53.3% price change compared with -56.4% for SLN. OmniAb is the larger company by market cap ($677.5 million vs $591.7 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | OABI | SLN |
|---|---|---|
| Share price | $4.66 | $9.52 |
| Market cap | $677.52M | $591.71M |
| 1-day change | +2.19% | -3.05% |
| YTD return | +151.89% | +56.58% |
| 1-year return | +166.29% | +81.33% |
| 5-year return | -53.26% | -56.37% |
| EPS (TTM) | $-0.36 | $-1.29 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $5.43 | $17.58 |
| 52-week low | $1.30 | $4.19 |
| Distance from 52-week high | -14.18% | -45.84% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +78.76% | +246.64% |
| Average volume | 1.47M | 1.14M |
| Shares outstanding | 145.39M | 62.15M |
| Employees | 89 | 88 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Commercial Physical & Biological Resarch | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- OABI has outperformed SLN by 85.0 percentage points over the past year.
About OmniAb
OABI stock →OmniAb, Inc., a biotechnology company, licenses discovery research technology to pharmaceutical and biotech companies, and academic institutions to enable the discovery of therapeutics in the United States, Europe, Japan, China, and Canada. The company's technology platform creates and screens diverse antibody repertoires to identify optimal antibodies and other target-binding proteins for partners' drug development efforts.
Health Care · Biotechnology: Commercial Physical & Biological Resarch · 89 employees
About Silence Therapeutics Plc American Depository Share
SLN stock →Silence Therapeutics plc, a biotechnology company, engages in the discovery and development of novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company develops Divesiran (SLN124), which is in Phase 2 development for polycythemia vera, and SLN548 for complement-mediated renal diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 88 employees
OABI vs SLN FAQ
Which is bigger, OmniAb or Silence Therapeutics Plc American Depository Share?
OmniAb (OABI) is larger, with a market capitalization of $677.52M compared with $591.71M for Silence Therapeutics Plc American Depository Share (SLN).
Which stock has performed better over the past year, OABI or SLN?
OABI returned +166.29% over the past 12 months, compared with +81.33% for SLN (price return, excluding dividends). Past performance does not predict future results.
Are OmniAb and Silence Therapeutics Plc American Depository Share in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Commercial Physical & Biological Resarch for OmniAb and Biotechnology: Pharmaceutical Preparations for Silence Therapeutics Plc American Depository Share.